|
Atazanavir, sold under the trade name Reyataz, is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once-daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. Atazanavir is the first PI approved for once-daily dosing, and also appears to be less likely to cause lipodystrophy and elevated cholesterol as side effects. It may also not be cross-resistant with other PIs. When boosted with ritonavir it is equivalent in potency to lopinavir for use in ''salvage'' therapy in patients with a degree of drug resistance, although boosting with ritonavir reduces the metabolic advantages of atazanavir. It is on the World Health Organization's List of Essential Medicines, the most important medication needed in a basic health system. ==Medical uses== Atazanavir is used in the treatment of HIV. The efficacy of atazanavir has been assessed in a number of well designed trials in ART-naive and ART-experienced adults.〔Croom KF, Dhillon S, Keam SJ.().Drugs 2009;69(8):1107-1140. .〕 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「atazanavir」の詳細全文を読む スポンサード リンク
|